Impact of prostate biopsy secondary pathology review on radiotherapy management.
Michael SiedowMariah EisnerAlexander YaneyIman WashingtonDebra ZyngerDouglas MartinXiaokui MoDominic DiconstanzoDayssy Alexandra DiazPublished in: The Prostate (2021)
We found nearly one in five men (18.7%) was assigned a different NCCN risk group and thus offered potentially different treatment options after a secondary pathology review at our institution. Given the inherent nature of prostate cancer and lung disease-specific survival associated with modern therapies, our study demonstrates the importance of a secondary pathology review and its potential impact on radiation therapy recommendations.